ErythroMer Blood Substitute

Background

4.5 million Americans receive blood transfusions each year, but human blood is limited by its supply and availability. under development, including Perfluorocarbon-Based Oxygen Carriers (PBOC) and Cell-Free Hemoglobin Based Carriers (HBOC), have mostly failed to preserve key physiologic functions of human blood cells. An effective artificial blood substitute will likely create and fulfill market demands for applications including hemorrhagic stock and emergency blood supplies.

Technology Description

ErythroMer is a novel blood substitute composed of a patented nanobialys nanoparticle. It is developed by a team of Washington University and UIUC faculty led by Dr. Allan Doctor, Director of Pediatric Critical Care Medicine. Existing blood substitutes under development often trap nitric oxide unintentionally and fail to release oxygen in a context-specific manner. ErythroMer has multiple unique advantages by design: (1) Toroidal morphology resembling RBCs; (2) Physiologic O2 binding and release; (3) Simple system to inhibit Hb auto-oxidation; (4) Limited NO sequestration; (5) Amenability to lyophilization and reconstitution. As a validation of these advantages, ErythroMer has been shown to demonstrate superior performance than other blood substitutes in a rodent model.

Advantages

  • Binds and releases oxygen molecules in a context specific-manner
  • Retards nitric oxide trapping that may lead to vasoconstriction
  • Maintains functionality during circulation and can be lyophilized for storage
  • Shows superior performance than existing blood substitutes in a rodent model

Inventor Bio

Applications

, , , , , , ,

Patent Status

Patent Pending

Innovator(s)

Allan Doctor, MD
Philip Spinella, MD
Dipanjan Pan
Gregory Mark Lanza

WUSTL Case Number

009762

Licensing Contact

Paul Hippenmeyer, PhD